FY2024 Earnings Forecast for TriMas Issued By Zacks Research

TriMas Co. (NASDAQ:TRS) – Stock analysts at Zacks Research raised their FY2024 earnings per share estimates for TriMas in a report issued on Monday, January 27th. Zacks Research analyst M. Das now expects that the industrial products company will post earnings of $1.71 per share for the year, up from their prior estimate of $1.70. The consensus estimate for TriMas’ current full-year earnings is $1.69 per share. Zacks Research also issued estimates for TriMas’ Q2 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.48 EPS, FY2025 earnings at $2.04 EPS, Q1 2026 earnings at $0.50 EPS, Q2 2026 earnings at $0.53 EPS and Q3 2026 earnings at $0.56 EPS.

A number of other research firms have also recently weighed in on TRS. BWS Financial restated a “buy” rating and issued a $40.00 price target on shares of TriMas in a research note on Thursday, January 23rd. StockNews.com upgraded shares of TriMas from a “sell” rating to a “hold” rating in a research note on Wednesday, November 13th.

TriMas Price Performance

NASDAQ:TRS opened at $24.47 on Thursday. The firm has a fifty day simple moving average of $24.99 and a 200 day simple moving average of $25.44. TriMas has a 1-year low of $22.24 and a 1-year high of $28.51. The stock has a market capitalization of $992.75 million, a PE ratio of 38.23 and a beta of 0.67. The company has a current ratio of 2.83, a quick ratio of 1.44 and a debt-to-equity ratio of 0.60.

TriMas (NASDAQ:TRS) last posted its quarterly earnings data on Monday, November 4th. The industrial products company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.14). The firm had revenue of $229.36 million for the quarter, compared to analyst estimates of $239.33 million. TriMas had a return on equity of 9.21% and a net margin of 2.93%. The firm’s quarterly revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.57 earnings per share.

Institutional Investors Weigh In On TriMas

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of TriMas by 3.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,461 shares of the industrial products company’s stock worth $982,000 after acquiring an additional 1,227 shares during the last quarter. Barclays PLC grew its stake in shares of TriMas by 341.3% in the third quarter. Barclays PLC now owns 68,792 shares of the industrial products company’s stock worth $1,755,000 after purchasing an additional 53,203 shares during the last quarter. XTX Topco Ltd purchased a new position in TriMas during the 3rd quarter valued at about $371,000. Jane Street Group LLC raised its position in TriMas by 74.4% during the 3rd quarter. Jane Street Group LLC now owns 82,621 shares of the industrial products company’s stock valued at $2,109,000 after purchasing an additional 35,258 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in TriMas by 10.7% during the 3rd quarter. Wellington Management Group LLP now owns 2,619,359 shares of the industrial products company’s stock valued at $66,872,000 after acquiring an additional 252,537 shares in the last quarter. 99.42% of the stock is currently owned by institutional investors.

TriMas Company Profile

TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.